How I treat splenomegaly in myelofibrosis

Blood Cancer Journal

Volumn 1, Issue 10, 2011, Pages

  Cervantes, F ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

JAK2 inhibitors; Myelofibrosis; Splenectomy; Splenomegaly; Therapy

Indexed keywords

ALPHA INTERFERON; BUSULFAN; DANAZOL; ERYTHROPOIETIN; HYDROXYUREA; JANUS KINASE 2 INHIBITOR; LENALIDOMIDE; LESTAURTINIB; MELPHALAN; MOMELOTINIB; N TERT BUTYL 3 [5 METHYL 2 [4 [2 (1 PYRROLIDINYL)ETHOXY]PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; PEGINTERFERON; POMALIDOMIDE; RUXOLITINIB; THALIDOMIDE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CYTOPENIA; DIARRHEA; DRUG EFFICACY; GASTROINTESTINAL DISEASE; GRAFT FAILURE; HEADACHE; HEPATOMEGALY; HISTOPATHOLOGY; HUMAN; LEUKOCYTOSIS; LIFE EXPECTANCY; MORBIDITY; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUTROPENIA; PANCYTOPENIA; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PORTAL HYPERTENSION; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE INFECTION; POSTOPERATIVE THROMBOSIS; RADIATION DOSE; SPLEEN SIZE; SPLENECTOMY; SPLENOMEGALY; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84864037614     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2011.36     Document Type: Article

References (53)

1. Barosi G. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 1999; 17: 2954-2970. (Pubitemid 29415257)
2. Mesa RA, Verstovsek S, Cervantes F, Barosi G, Reilly JT, Dupriez B et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Leuk Res 2007; 31: 737-740. (Pubitemid 46855906)
3. Jacobson RJ, Salo A, Fialkow PJ. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood 1978; 51: 189-194. (Pubitemid 8284647)
4. Buschle M, Janssen JW, Drexler H, Lyons J, Anger B, Bartram CR. Evidence of pluripotent stem cell origin of idiopathic myelofibrosis: clonal analysis of a case characterized by a N-ras gene mutation. Leukemia 1988; 2: 658-660.
5. Kralowics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweig JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790. (Pubitemid 40570926)
6. Baxter EJ, Scott LM, Campbell PJ, East C, Fouroclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061. (Pubitemid 40386783)
7. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-397. (Pubitemid 40544655)
8. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 2005; 434: 1144-1148. (Pubitemid 40663494)
9. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, GozoM et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PloS Med 2006; 3: 1140-1151. (Pubitemid 44125998)
10. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108: 3472-3476.
11. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E et al. A new prognostic scoring system for primary myelofibrosis based on a study of the international working group for myelofibrosis research and treatment. Blood 2009; 113: 2895-2901.
12. Passamonti F, Cervantes F, Vannucchi A, Morra E, Rumi E, Pereira A et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the international working group for myeloproliferative neoplasms research and treatment. Blood 2010; 115: 1703-1708.
13. Gangat N, Pardanani A, Hanson CA, Van Dyke DL, Begna KH, Vaidya R et al. DIPSS-Plus: a refined dynamic international prognostic scoring system(DIPSS) for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count and transfusion status. J Clin Oncol 2011; 29: 392-397.
14. Guardiola P, Anderson JE, Bandini G, Cervantes F, Runde V, Arcese W et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Societé Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 1999; 93: 2831-2838. (Pubitemid 29200773)
15. Ballen KK, Shrestha S, Sobocinski KA, Zhang MJ, Bashey A, Bolwell BJ et al. Outcome of transplantation for myelofibrosis. Biol Bone Marrow Transplant 2010; 16: 358-367.
16. Kröger N, Holler E, Kobbe G, Bornhäuser M, Schwerdtfeger R, Baurmann H et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009; 114: 5264-5270.
17. Zhang B, Lewis SM. The splenomegalyof myeloproliferative and lymphoproliferative disorders: splenic cellularity and vascularity. Eur J Haematol 1989; 43: 63-66. (Pubitemid 19208641)
18. Tefferi A. How I treat myelofibrosis. Blood 2011; 117: 3494-3504.
19. Cervantes F. Modern management of myelofibrosis. Br J Haematol 2005; 128: 583-592. (Pubitemid 40343226)
20. Lofvenberg E, Wahlin A, Roos G, Ost A. Reversal of myelofibrosis by hydroxyurea. Eur J Haematol 1990; 44: 33-38. (Pubitemid 20118419)
21. Manoharan A. Management of myelofibrosis with intermittent hydroxyurea. Br J Haematol 1991; 77: 252-254.
22. Martínez-Trillos A, Gaya A, Maffioli M, Arellano-Rodrigo E, Calvo X, Díaz-Beyá M et al. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Ann Hematol 2010; 89: 1233-1237.
23. Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg J, Reilly JT et al. International Working Group consensus criteria for treatment response in myelofibrosis with myeloid metaplasia: on behalf of the IWG for myelofibrosis research and treatment (IWG-MRT). Blood 2006; 108: 1497-1503. (Pubitemid 44316114)
24. Oishi N, Swisher SN, Troup SB. Busulfan therapy in myeloid metaplasia. Blood 1960; 15: 863-872.
25. Petti MC, Latagliata R, Spadea T, Spadea A, Montefusco E, Aloe Spiriti MA et al. Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2002; 116: 576-581. (Pubitemid 34178656)
26. Tefferi A, Silverstein MN, Li C-Y. 2-Chlorodeoxyadenosine treatment after splenectomy in patients who have myelofibrosis with myeloid metaplasia. Br J Haematol 1997; 99: 352-357. (Pubitemid 27497566)
27. Barosi G, Liberato LN, Costa A, Ascari E. Cytoreductive effect of recombinant alpha interferon in patients with myelofibrosis with myeloid metaplasia. Blut 1988; 58: 271-274.
28. Gilbert HS. Long term treatment of myeloproliferative disease with interferon alpha-2b: feasibility and efficacy. Cancer 1998; 83: 1205-1213. (Pubitemid 28419075)
29. Bachleitner-Hofmann T, Gisslinger H. The role of interferon-á in the treatment of idiopathic myelofibrosis. Ann Hematol 1999; 78: 533-538. (Pubitemid 30009354)
30. Ianotto JC, Kiladjian JJ, Demory JL, Roy L, Boyer F, Rey J et al. PEG-IFN-alpha-2a therapy in patients with myelofibrosis: a study of the French Groupe d'Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myeloproliferatifs (FIM). Br J Haematol 2009; 146: 223-225.
31. Mesa RA, Steensma DP, Pardanani A, Li CY, Elliott M, Kaufmann SH et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003; 101: 2534-2541. (Pubitemid 36857609)
32. Marchetti M, Barosi G, Balestri F, Viarengo G, Gentili S, Barulli S et al. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. J Clin Oncol 2004; 22: 424-431. (Pubitemid 41079770)
33. Merup M, Kutti J, Birgergard G, Mauritzson N, Björkholm M, Markevärn B et al. Negligible effects of thalidomide in patients with myelofibrosis with myeloid metaplasia. Med Oncol 2002; 19: 79-86. (Pubitemid 34625929)
34. Abgrall JF, Guibaud I, Bastie JN, Flesch M, Rossi JF, Lacotte-Thierry L et al. Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study. Haematologica 2006; 91: 1027-1032. (Pubitemid 44204767)
35. Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006; 108: 1158-1164. (Pubitemid 44232010)
36. Benbassat J, Penchas S, Ligumski M. Splenectomy in patients with agnogenic myeloid metaplasia: an analysis of 321 published cases. Br J Haematol 1979; 42: 207-214. (Pubitemid 9188193)
37. Barosi G, Ambrosetti A, Buratti A, Finelli C, Liberato NL, Quaglini S et al. Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction. Leukemia 1993; 7: 200-206. (Pubitemid 23079228)
38. Tefferi A, Mesa RA, Nagomey DN, Schroeder G, Silverstein MN. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 2000; 95: 2226-2233. (Pubitemid 30167718)
39. López-Guillermo A, Cervantes F, Bruguera M, Pereira A, Feliu E, Rozman C. Liver dysfunction following splenectomy in idiopathic myelofibrosis: a study of 10 patients. Acta Haematol 1991; 85: 184-188.
40. Chaffanjon PC, Brichon PY, Ranchoup Y. Portal vein thrombosis following splenectomy for hematologic disease: retrospective study with Doppler color flow imaging. World J Surg 1998; 22: 1082-1086. (Pubitemid 28428055)
41. Barosi G, Ambrosetti A, Centra A, Falcone A, Finelli C, Foa P et al. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Blood 1998; 91: 3630-3636. (Pubitemid 28225729)
42. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011; 29: 761-770.
43. Elliott MA, Chen MG, Silverstein MN, Tefferi A. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Br J Haematol 1998; 103: 505-511. (Pubitemid 28522460)
44. Wagner Jr H, McKeough PG, Desforges J, Madoc-Jones H. Splenic irradiation in the treatment of patients with chronic myelogenous leukemia or myelofibrosis with myeloid metaplasia. Results of daily and intermittent fractionation with and without concomitant hydroxyurea. Cancer 1986; 58: 1204-1207. (Pubitemid 16053129)
45. Bouabdallah R, Coso D, Gonzague-Casabianca L, Alzieu C, Resbeut M, Gastaut JA. Safety and efficacy of splenic irradiation in the treatment of patients with idiopathic myelofibrosis: a report on 15 patients. Leuk Res 2000; 24: 491-495. (Pubitemid 30227227)
46. Koeffler HP, Cline MJ, Golde DW. Splenic irradiation in myelofibrosis: effect on circulating myeloid progenitor cells. Br J Haematol 1979; 43: 69-77. (Pubitemid 9251449)
47. Pardanani A, Brown P, neben-Wittich M, Tobin R, tefferi A. Effective management of accelerated phase myelofibrosis with low-dose splenic radiotherapy. Am J Hematol 2010; 85: 715-716.
48. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes- Franco J, Thomas DA et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010; 363: 1117-1127.
49. Verstovsek S, Mesa RA, Gottlib JR, Levy RS, Gupta V, Di Persio JF et al. Results of COMFORT-I, a randomized double-blind phase III trial of JAK 12 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). J Clin Oncol 2011; 29(Suppl) abstract 6500.
50. Harrison CN, Kiladjian J, Al-Ali HK, Gisslinger R, Waltzman RJ, Stalbovskaya V et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia-myelofibrosis (PET-MF). J Clin Oncol 2011; 29(Suppl) abstract LBA6501.
51. Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011; 29: 789-796.
52. Santos FP, Kantarjian HM, Jain N, Manshouri T, Thomas DA, Garcia-Manero G et al. Phase II study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post polycythemia vera/essential thrombocythemia myelofibrosis. Blood 2010; 115: 1131-1136.
53. Pardanani AD, Caramazza D, George G, Lasho T, Hogan WJ, Litzow MR et al. Safety and efficacy of CYT387, a JAK 12 inhibitor, for the treatment of myelofibrosis. J Clin Oncol 2011; 29(Suppl) abstract 6614.